Exploring the lived experiences of individuals with cystic fibrosis after the implementation of elexacaftor/tezacaftor/ivacaftor for treatment
Therapeutic Advances in Respiratory Disease · 2026-07 · 20
DOI: 10.1177/17534666261469021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Respiratory Disease, online erschienen am 25.07.2026. Verfasst von Alyssa Riggle und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Case Western Reserve University, Cleveland, OH 44106-4915, USA. Hauptthemen laut MEDLINE: Cystic Fibrosis, Indoles, Aminophenols, Quinolones. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
CFTR modulators are a class of medications prescribed to people with cystic fibrosis (pwCF) who have certain genetic mutations. In 2019, elexacaftor/tezacaftor/ivacaftor (ETI) was approved by the FDA and led to significant health improvements for pwCF. Despite ETI showing significant health improvements compared to prior modulators, little is known about how ETI impacts the lived experience of pwCF.
Objectives
This study explored how the implementation of ETI in cystic fibrosis treatment has impacted the lived experience of pwCF and what additional resources healthcare providers should be offering to their patients.
Design
We conducted a qualitative study that recruited pwCF from an adult CF center who were over the age of 18 and had been on ETI for at least a year.
Methods
We conducted and recorded semi-structured interviews with participants over the Zoom platform. Dedoose was used to code the data and themes were constructed using inductive coding rooted in grounded theory.
Results
Four themes were constructed from the data in this study: (1) “transformation in health” refers to the change in physical health the participants have noticed since starting ETI, (2) “future planning and opportunities” highlights new opportunities becoming available and a new desire to plan for the future, (3) “impact on relationships” describes how participants felt their relationships with their partner, family, and care teams, were impacted by ETI, (4)“new worries and struggles” describes new struggles and concerns that participants have faced.
Conclusion
The data from this study provide evidence that ETI has not only impacted pwCF on a physical level, but may also have an impact on relationships, mental health, and future planning. It also highlights the need for additional resources that CF care teams should be providing to their patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Case Western Reserve University, Cleveland, OH 44106-4915, USA.
- TriHealth Precision Medicine Institute, Montgomery, OH, USA.
- Department of Pediatric Pulmonology, University Hospitals Rainbow Babies and Children's Hospital, Cleveland, OH, USA.
- Department of Bioethics, Case Western Reserve University, Cleveland, OH, USA.
- Department of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH, USA.
ORCID-Profile: Alyssa Riggle
Zitieren
APA
Riggle, A., Page, A., Roesch, E., Michie, M., & Darrah, R. (2026). Exploring the lived experiences of individuals with cystic fibrosis after the implementation of elexacaftor/tezacaftor/ivacaftor for treatment. Therapeutic Advances in Respiratory Disease, 20. https://doi.org/10.1177/17534666261469021
Vancouver
Riggle A, Page A, Roesch E, Michie M, Darrah R. Exploring the lived experiences of individuals with cystic fibrosis after the implementation of elexacaftor/tezacaftor/ivacaftor for treatment. Therapeutic Advances in Respiratory Disease. 2026;20. doi:10.1177/17534666261469021
BibTeX
@article{Riggle2026,
author = {Riggle, Alyssa and Page, Annelise and Roesch, Erica and Michie, Marsha and Darrah, Rebecca},
title = {Exploring the lived experiences of individuals with cystic fibrosis after the implementation of elexacaftor/tezacaftor/ivacaftor for treatment},
journal = {Therapeutic Advances in Respiratory Disease},
year = {2026},
volume = {20},
doi = {10.1177/17534666261469021}
}
EUVIMED